A phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women
A single intranasal dose of 10 mg zavegepant was generally safe and well tolerated in healthy lactating women and the estimated infant exposure to zavegepant via breast milk is very low.
Authors
- Jing Liu (ORCID: https://orcid.org/0000-0001-9481-5961)
- Ogert Fisniku
- Abhijeet Jakate (ORCID: https://orcid.org/0009-0000-2196-5782)
- Kayce Morton
- Mohamed H. Shahin (ORCID: https://orcid.org/0009-0000-1060-0737)
- Yan Weng
- Benjamin Maligalig
- Ani Shkrodova
- Ding Ding
- Pamela Garnick
Institutions
- Pfizer (United States) (US)
- Makati Medical Center (PH)
- University of Makati (PH)
- Phoenix Children's Hospital (US)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1111/head.70036
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer